Health Report Equatorial Guinea: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Report Equatorial Guinea.

Press releases published on October 7, 2026

Oct. 7, 2026

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

Indeterminate GlobeNewswire

Oct. 7, 2026

Theialife Announces Positive Type C Meeting with FDA for ND10 in Progressive Myopia

Indeterminate GlobeNewswire

Oct. 7, 2026

Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib

Indeterminate GlobeNewswire

Oct. 7, 2026

Cyllene Therapeutics Presents Interim Data from Phase 1b/2a Clinical Trial Showing EG110A Reduced Urinary Episodes in Patients with Spinal Cord Injury at the International Continence Society (ICS) Conference

Indeterminate GlobeNewswire

Oct. 7, 2026

BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

Indeterminate GlobeNewswire

Oct. 7, 2026

Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications

Indeterminate GlobeNewswire

Oct. 7, 2026

TOMI Environmental Solutions Confirms Readiness to Support Biosecurity Preparedness and Front-Line Response Worldwide

Indeterminate GlobeNewswire

Oct. 7, 2026

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Indeterminate GlobeNewswire

Oct. 7, 2026

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

Indeterminate GlobeNewswire

Oct. 7, 2026

Guelph psychotherapist preparing to ask Queen’s Park for OHIP coverage of psychotherapy

Indeterminate GlobeNewswire

Oct. 7, 2026

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

Indeterminate GlobeNewswire

Oct. 7, 2026

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire

Oct. 7, 2026

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Indeterminate GlobeNewswire

Oct. 7, 2026

Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field

Indeterminate GlobeNewswire

Oct. 7, 2026

AltruBio to Present Data from ALTB-268 Phase 2a Trial on Ulcerative Colitis at United European Gastroenterology (UEG) Week 2026

Indeterminate GlobeNewswire

Oct. 7, 2026

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Indeterminate GlobeNewswire

Oct. 7, 2026

Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

Indeterminate GlobeNewswire

Oct. 7, 2026

Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease

Indeterminate GlobeNewswire

Oct. 7, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Indeterminate GlobeNewswire

Oct. 7, 2026

Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide

Indeterminate GlobeNewswire